Aclaris Therapeutics ACRS Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aclaris Therapeutics's accrued liabilities, current?
- Aclaris Therapeutics (ACRS) reported accrued liabilities, current of $5.9M in Q1 2026.
- How has Aclaris Therapeutics's accrued liabilities, current changed year-over-year?
- Aclaris Therapeutics's accrued liabilities, current decreased by 31.2% year-over-year, from $8.57M to $5.9M.
- What is the long-term trend for Aclaris Therapeutics's accrued liabilities, current?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's accrued liabilities, current has grown at a 8.3% compound annual growth rate (CAGR), from $5.91M to $8.79M.